News

Video

Data from the DEAR Real-World Study and Strategies for Optimizing Outcomes

Author(s):

Rana R. McKay, MD,Tanya B. Dorff, MD

Drs. Dorff and McKay discuss real-world data from DEAR trial comparing darolutamide, enzalutamide and apalutamide, providing clinical pearls on their experiences to optimize outcomes.

Related Videos
Louis Crain Garrot, MD
Bradley C. Carthon, MD, PhD
Fred Saad, CQ, MD, FRCS, FCAHS, director, Prostate Cancer Research, Montreal Cancer Institute, Centre Hospitalier de l’Université de Montréal; full professor, Department of Surgery, Université de Montréal; uro-oncologist, Urology Department, University of Montreal Health Center
Bertram Yuh, MD, MISM, MSHCPM
Fred Saad, CQ, MD, FRCS, FCAHS
Fred Saad, CQ, MD, FRCS, FCAHS
Alicia Morgans, MD, MPH
Jacob E. Berchuck, MD
Alicia Morgans, MD, MPH
Anthony V. D'Amico, MD, PhD
Related Content
The OncFive: Top Oncology Articles for the Week of 11/10
November 16th 2024

The OncFive: Top Oncology Articles for the Week of 11/10

Neeraj Agarwal, MD
July 17th 2023

FDA Approval Insights: Talazoparib Plus Enzalutamide in HRR Gene–Mutated mCRPC

David Parkinson, MD, president, chief executive officer, ESSA
November 1st 2024

ESSA Discontinues Phase 2 Study of Masofaniten Plus Enzalutamide in mCRPC

Andrew J. Armstrong, MD, MSc
June 15th 2023

FDA Approval Insights: Olaparib Plus Abiraterone in BRCA-Mutated mCRPC

Bradley C. Carthon, MD, PhD
October 30th 2024

Patients Characteristics, Sequencing Considerations Are Vital in Prostate Cancer Management

FDA Receives NDA for 3-Month Version of Leuprolide Mesylate for Advanced Prostate Cancer
October 30th 2024

FDA Receives NDA for 3-Month Version of Leuprolide Mesylate for Advanced Prostate Cancer